UNSPSC 51285700: Antibacterial amides

This classification denotes antibacterials composed of organic compounds containing the -CO-NH2 radical (amides).

UNSPSC 51285700 Antibacterial amides, a Class code, encompasses pharmaceuticals and over-the-counter health products purchased by state and local governments — specifically naloxone, generic pharmaceutical formulations, first aid and medical supplies, and OTC products acquired for public health, emergency response, and employee health programs. Recent opportunities show state and local health departments, fire departments, and cooperative purchasing alliances procuring these items through competitive bidding, RFPs, and RFIs in volumes ranging from hundreds to thousands of units annually, with delivery and compliance requirements tied to FDA standards, shelf-life minimums, and federal regulatory frameworks including the Drug Supply Chain Security Act. Issuing bodies include county health departments, municipal fire and rescue divisions, state health and human services agencies, and multistate cooperative purchasing organizations. The code captures both direct pharmaceutical procurement and broader medical supply acquisition for emergency response and public health initiatives.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, response due July 26, 2023. The City of Tampa's Purchasing Department posted IFB 26P00145 in March 2026 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a certified Small Local Business Enterprise set-aside offering a 5% bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities across multiple jurisdictions including Oregon, with proposals due March 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs supporting its Therapeutic Pharmacy Initiative.